Literature DB >> 18608926

Th17 cells in the setting of Aspergillus infection and pathology.

Teresa Zelante1, Silvia Bozza, Antonella De Luca, Carmen D'Angelo, Pierluigi Bonifazi, Silvia Moretti, Gloria Giovannini, Francesco Bistoni, Luigina Romani.   

Abstract

Innate and adaptive immune responses act to generate the most effective form of immunity for protection against Aspergillus fumigatus. The decision of how to respond is still primarily determined by interactions between fungi and cells of the innate immune system, but the actions of T cells will feed back into this dynamic equilibrium to regulate the balance between pro-inflammatory and anti-inflammatory signals. The enzyme indoleamine 2,3-dioxygenase, and tryptophan metabolites, acting as a bridge between dendritic cells and regulatory T cells, pivotally contribute to such a homeostatic condition by taming inflammatory responses. IL-23 and the newly described Th17 pathway, by means of negative regulation of tryptophan catabolism, play an inflammatory role previously attributed to uncontrolled Th1 response. Our data support a model in which IL-23/IL-17A/Th17-driven inflammation promotes infection and impairs antifungal immune resistance. Thus, modulation of the inflammatory response represents a potential strategy to stimulate protective immune responses to Aspergillus.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18608926     DOI: 10.1080/13693780802140766

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  37 in total

Review 1.  Current understanding of Pneumocystis immunology.

Authors:  Michelle N Kelly; Judd E Shellito
Journal:  Future Microbiol       Date:  2010-01       Impact factor: 3.165

Review 2.  Host immune defense against Aspergillus fumigatus: insight from experimental systemic (disseminated) infection.

Authors:  I Mirkov; S Stosic-Grujicic; M Kataranovski
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

Review 3.  Are Th17 Cells Playing a Role in Immunity to Dermatophytosis?

Authors:  Marie-Pierre Heinen; Ludivine Cambier; Laurence Fievez; Bernard Mignon
Journal:  Mycopathologia       Date:  2016-11-23       Impact factor: 2.574

4.  Anti-Aspergillus human host defence relies on type 1 T helper (Th1), rather than type 17 T helper (Th17), cellular immunity.

Authors:  Louis Y A Chai; Frank van de Veerdonk; Renoud J Marijnissen; Shih-Chin Cheng; Ai Leng Khoo; Magda Hectors; Katrien Lagrou; Alieke G Vonk; Johan Maertens; Leo A B Joosten; Bart-Jan Kullberg; Mihai G Netea
Journal:  Immunology       Date:  2009-12-02       Impact factor: 7.397

5.  Interplay between effector Th17 and regulatory T cells.

Authors:  Amit Awasthi; Gopal Murugaiyan; Vijay K Kuchroo
Journal:  J Clin Immunol       Date:  2008-09-23       Impact factor: 8.317

Review 6.  Fungus-Specific CD4 T Cells as Specific Sensors for Identification of Pulmonary Fungal Infections.

Authors:  Alexander Scheffold; Carsten Schwarz; Petra Bacher
Journal:  Mycopathologia       Date:  2017-11-22       Impact factor: 2.574

Review 7.  Aspergillosis and stem cell transplantation: An overview of experimental pathogenesis studies.

Authors:  Nadia Al-Bader; Donald C Sheppard
Journal:  Virulence       Date:  2016-09-29       Impact factor: 5.882

8.  Innate immune recognition of molds and homology to the inner ear protein, cochlin, in patients with autoimmune inner ear disease.

Authors:  Shresh Pathak; Lynda J Hatam; Vincent Bonagura; Andrea Vambutas
Journal:  J Clin Immunol       Date:  2013-08-03       Impact factor: 8.317

Review 9.  Clinical consequences of targeting IL-17 and TH17 in autoimmune and allergic disorders.

Authors:  Keven M Robinson; Michelle L Manni; Partha S Biswas; John F Alcorn
Journal:  Curr Allergy Asthma Rep       Date:  2013-12       Impact factor: 4.806

10.  Aspergillus and Fusarium corneal infections are regulated by Th17 cells and IL-17-producing neutrophils.

Authors:  Patricia R Taylor; Sixto M Leal; Yan Sun; Eric Pearlman
Journal:  J Immunol       Date:  2014-03-03       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.